Posted on August 8, 2017 by Sitemaster
Immune checkpoint inhibitors include drugs like ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), and others that can have dramatic effects on the survival of some groups of patients with advanced forms of some cancers. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antibody, checkpoint, immune, inhibitor, outcome, test, trial | 4 Comments »
Posted on May 18, 2017 by Sitemaster
There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: inhibitor, mCRPC, PARP, Phase III, trial | Leave a comment »
Posted on March 7, 2017 by Sitemaster
A second PARP inhibitor has recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with BRCA1/2 mutations and advanced ovarian cancer who have already received two types of chemotherapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: advanced, BRCA1/2, inhibitor, PARP | 3 Comments »
Posted on July 14, 2016 by Sitemaster
New immunotherapeutic drugs known as PD-1 inhibitors (drugs like nivolumab/Optivo and pembrolizumab/Keytruda) have shown some remarkable effects in the treatment of advanced forms of cancer like melanoma and some forms of lung cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, efficacy, inhibitor, outcome, PD-1 | Leave a comment »
Posted on June 13, 2016 by Sitemaster
Another important set of data that came out of the ASCO session that your sitemaster was unable to attend were the data presented by Dr. Maha Hussain on the use of the PARP inhibitor veliparib. …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, mCRPC, metastatic, PARP, veliparib | 2 Comments »
Posted on April 6, 2016 by Sitemaster
Johnson & Johnson has just acquired the rights to develop and sell a drug called niraparib for the treatment of prostate cancer everywhere in the world except Japan. The developer, Waltham, MA-based Tesaro, has retained the rights to niraparib in Japan. … READ MORE …
Filed under: Drugs in development | Tagged: advanced, inhibitor, niraparib, PARP, trials | Leave a comment »
Posted on October 28, 2015 by Sitemaster
A paper in the New England Journal of Medicine now provides detailed information about the activity of the PARP inhibitor olaparib in the treatment of carefully selected patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, Lynparza, mCRPC, metastatic, olaparib, PARP | 3 Comments »